Applied DNA Seeks Approval For PCR-Based Monkeypox Virus Test

Author: Vandana Singh | August 19, 2022 11:32am

• Applied DNA Sciences Inc (NASDAQ:APDN) has submitted to the New York State Department of Health (NYSDOH) a validation package for its monkeypox virus test in support of a request for full approval as a form of NYSDOH Laboratory Developed Test (LDT). 
• The PCR-based diagnostic is designed to identify the genetic signature of the Clade II variant of the monkeypox virus currently prevalent in the U.S. 
• Related Content: Applied DNA Sciences Shares Triples After Monkeypox Diagnostic Test Update.
• Named the Linea Monkeypox Virus 1.0 Assay, the test would be the company's second successful LDT in less than one year if approved by the NYSDOH. 
• Currently, the FDA has cleared one test to detect monkeypox, offered through the U.S. Centers for Disease Control and Prevention as an LDT. 
• Applied DNA Sciences' Linea 2.0 COVID-19 Assay received conditional approval as an LDT from NYSDOH in January 2022.
• Earlier this week, Chembio Diagnostics Inc (NASDAQ: CEMI) said it is evaluating the potential to develop a monkeypox rapid point-of-care (POC) test. 
• Price Action: APDN shares are up 11.90% at $4.03 on the last check Thursday.
• Photo Jernej Furman from Flickr

Posted In: APDN BVNKF BVNRY BWV CEMI EBS GOVX SIGA TNXP WETG